In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Harmonisation

This article was originally published in RAJ Devices

Executive Summary

GHTF revises proposed STED document

You may also be interested in...



QUOTED. 9 July 2020. Angelo De Rosa.

Boston Scientific’s VP of cardiac rhythm management business in Europe, the Middle East and Africa, Angelo De Rosa, talked to Medtech Insight about opportunities to accelerate digital health transformation during the COVID-19 crisis. See what De Rosa said about it here.

The Cost Of ‘Stacking’ Orphan Indications And A Case For Reform

Restricting orphan drug approvals could save the US billions of dollars, study from University of California’s Center for Health Policy and Economics suggests.

Keeping Track: Biogen’s Aducanumab Headlines Midsummer Submission Round-Up

The latest application submission news and highlights from the Pink Sheet’s US FDA Performance Tracker.

UsernamePublicRestriction

Register

LL025498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel